Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin and Probiotics in IBS-D
NCT04074421Phase 4Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2020
- Primary completion
- Jun 2022
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bacillus subtilis in Irritable bowel syndrome with diarrhea (IBS-D) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: IBS Symptom Grade Score at 12 weeks, IBS Quality of Life Score at 12 weeks and 1 more. Status: unknown.
02
Drugs
bacillus subtilis
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT04074421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074421.